| Target Audience |
| This activity has been designed to meet the educational needs of healthcare practitioners involved in the care of patients with HBV. |
| |
| Statement of Need/Program
Overview |
| The goal of this program is to provide important clinical data on the management of HBV. |
| |
| Educational Objectives |
| Upon completion of this activity, participants should be better able to: |
|
• |
Analyze new data reported at Digestive Disease Week 2011 on the management and treatment of chronic hepatitis B and how these data might impact current patient care |
| • |
Compare treatment outcomes following nucleos(t)ide therapy for chronic hepatitis B in the community setting with outcomes from registration trials and outcomes in Asian patients with outcomes in non-Asian patients |
| • |
Recognize the problem of HBV viremia recurrence when nucleos(t)ide therapy is stopped following HBeAg seroconversion |
| • |
Evaluate the effectiveness of prophylactic treatment with entecavir in preventing HBV reactivation in patients undergoing cancer chemotherapy |
|
| |
| Physician Accreditation
Statement |
| This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. |
| |
| Credit Designation |
| Purdue University College of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| |
| Faculty Disclosure Statement |
| All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Dr. Tran receives grants and is a consultant for Gilead, BMS, Idenix, and Schering Pharmaceuticals. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. The Focus Medical Communications staff and Purdue University School of Pharmacy staff have no relationships to disclose. |
| |
